The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction
NCT ID: NCT05495958
Last Updated: 2022-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
56 participants
INTERVENTIONAL
2022-07-25
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary outcome is the change in Ocular surface disease index and 5-Item Dry Eye Questionnaire score assessed before the topical treatment and every one-months until 3 months. The secondary outcome measures are Tear breakup time, Schirmer test, Corneal fluorescein staining, Meibomian gland expressibility.
The grader and the patients will blind to the study group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Statin Eye Drop in the Management of the Dry Eye
NCT06208384
Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
NCT02958514
Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device
NCT03788486
Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease
NCT05865457
Eyelid Androgen Treatment in Dry Eye
NCT06154200
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prescribe topical placebo eye drop
Topical placebo eye drop
The same-shape packed drop without vitamin D
Prescribe topical Vitamin D eye drop
Topical Vitamin D eye drop
25 Microgram/cc or 1000 IU
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topical Vitamin D eye drop
25 Microgram/cc or 1000 IU
Topical placebo eye drop
The same-shape packed drop without vitamin D
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients taking Vitamin D systemic Supplementation
* Patient with prior ocular surgeries within previous 6 months.
* Patient with other causes of dry eye, such as aqueous tear deficiency or ocular surface disease
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shahid Beheshti University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zahra Rabbani Khah
Head of Ophthalmic Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ophthalmic Research center
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.